Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Key Points: FK866 combined with bortezomib induces synergistic anti-MM cell death. Addition of low doses of NAD+-depleting agent FK866 overcomes bortezomib resistance in MM cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“1, no significant combination effect.(18)”
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“(1-3) In such a scenario, tumor cells exhibit highly increased rates of energy consuming reactions due to elevated intracellular NAD levels, with pyridine nucleotide linking bioenergetic processes and signalling pathways mediating tumor cell growth and survival.”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Proteasome inhibitor bortezomib has transformed therapy of relapsed MM, as well as prolonged event-free and overall survival when used as initial therapy for newly diagnosis disease.(14) However, prolonged bortezomib exposure may result in cumulative toxicity and acquisition of drug resistance.”
BackgroundSelf-citationNutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950 · cited 1×
“Sinclair, Harvard Medical School, Boston, MA).(11) MM1S and U266 cells were transfected with hNampt/pcDNA or pcDNA empty vector using the cell line Nucleofector Kit V or C solution (Amaxa Biosystems, Lonza, Basel, Switzerland), respectively, as per the manufacturer’s instructions.”
MethodUnderstanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · cited 1×
“Interaction of MM cells with the bone marrow (BM) microenvironment confers growth, survival, and drug resistance in tumor cells.(23) Thus we next tested the effect of BM stromal cells (BMSCs) on sensitivity of MM cells to combined FK866 plus bortezomib treatment.”
BackgroundSelf-citationThe secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694 · cited 1×
“Previous studies showed that bortezomib primarily inhibits CT-L and, to a lesser degree, C-L activity.(30) Here we observed that treatment ofMM1S cells for 6 hours with low-dose (2 nM) bortezomib inhibited 60%CT-L and 15%C-L activity, whereas FK866 (3 nM) for 48 hours inhibited only 40%CT-L and 3%C-L activities, as me…”
MethodSelf-citationChauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
Self-citationThe new life of a centenarian: signalling functions of NAD(P)
Berger, F. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.01.007 · Cited by 489
Watson, M., Roulston, A., Bélec, L., Billot, X., Marcellus, R., Bédard, D., Bernier, C., Branchaud, S., Chan, H., Dairi, K., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00112-09 · Cited by 229
Cited by
CD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G., & Malavasi, F. (2018) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 493
Self-citationInhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
Sampath, D., Zabka, T. S., Misner, D. L., O’Brien, T., & Dragovich, P. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.02.004 · Cited by 258
Vriend, J., & Reiter, R. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.12.013 · Cited by 246
“Depletion of NAD+, on the other hand, was found to enhance the effectiveness of the proteasome inhibitor, bortezomib, in myeloma cells (Cagnetta et al., 2013).”
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Galli, U., Colombo, G., Travelli, C., Tron, G. C., Genazzani, A. A., & Grolla, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00656 · Cited by 162
Kamihara, Y., Takada, K., Sato, T., Kawano, Y., Murase, K., Arihara, Y., Kikuchi, S., Hayasaka, N., Usami, M., Iyama, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11830 · Cited by 45
“Combination approaches have been proposed to prevent and/or overcome bortezomib resistance [37].”
Background
Metadata
- Authors
- Cagnetta, A., Cea, M., Calimeri, T., Acharya, C., Fulciniti, M., Tai, Y.-T., Hideshima, T., Chauhan, D., Zhong, M. Y., Patrone, F., Nencioni, A., Gobbi, M., Richardson, P., Munshi, N., & Anderson, K. C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-08-15
- Volume
- 122
- Issue
- 7
- Pages
- 1243-1255
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2090156221
- Cited by
- 86
- References
- 11
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. https://app.cochat.ai/papers/10.1182/blood-2013-02-483511
- The paper
- Cagnetta, A., Cea, M., Calimeri, T., Acharya, C., Fulciniti, M., Tai, Y.-T., Hideshima, T., Chauhan, D., Zhong, M. Y., Patrone, F., Nencioni, A., Gobbi, M., Richardson, P., Munshi, N., & Anderson, K. C. (2013). Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. Blood. https://doi.org/10.1182/blood-2013-02-483511
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.